Saturday 17 October 2026
Export PHG’s income statement to Excel — free account
Koninklijke Philips N.V.
PHG Healthcare Medical Devices
Koninklijke Philips N.V.’s revenue for fiscal 2025 (year ended December 2025) was $20.2 billion, up 3.47% from fiscal 2024. In the quarter to June 2026, revenue grew 2.94%, EPS grew 56.7%, free cash flow grew 49.7% and total debt fell 9.93%, each against the same quarter a year earlier.
25.74
0.25
+0.98%
Follow PHG
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
33.65 | 24.87 | 22.85 | 19.86 |
P/S ratio |
1.36 | 1.27 | 1.28 | 1.26 | |
P/FCF ratio |
0.00 | 44.24 | 14.78 | 14.05 | |
P/Operating CF |
71.24 | 16.23 | 118.50 | 59.63 | |
P/B ratio |
2.10 | 2.07 | 1.95 | 1.95 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.68 | 1.50 | 1.52 | 1.51 | |
EV/EBITDA |
11.16 | 10.50 | 10.26 | 9.19 | |
EV/Operating CF |
(93.09) | 22.83 | 12.26 | 11.98 | |
EV/FCF |
(25.95) | 52.15 | 17.59 | 16.85 | |
Quick Ratio |
0.76 | 0.86 | 0.80 | 0.73 | |
Current Ratio |
1.32 | 1.32 | 1.32 | 1.26 | |
Net Debt/EBITDA |
8.10 | 5.15 | 8.34 | 4.51 | |
Debt/Assets |
27.48% | 25.73% | 25.27% | 23.65% | |
Debt/Equity |
0.68 | 0.63 | 0.60 | 0.55 | |
Asset Turnover |
0.61 | 0.65 | 0.68 | 0.67 | |
Operating CF/Net income |
1.69 | 3.55 | 1.25 | 0.98 | |
Capex/Depreciation |
(0.51) | (0.70) | (0.60) | (0.40) | |
Interest Coverage |
4.22 | 4.94 | 2.90 | 6.42 | |
Research and Development Expense of Revenue |
9.62% | 8.49% | 10.09% | 11.10% | |
Selling, General and Administrative Expense of Revenue |
27.38% | 25.81% | 30.32% | 27.68% | |
Intangible Assets out of Total Assets |
0.45 | 0.44 | 0.45 | 0.46 | |
Share Based Compensation of Revenue |
0.80% | 0.50% | 0.77% | 1.17% | |
Graham Net Nets |
(0.29) | (0.27) | (0.27) | (0.26) | |
Graham Number |
15.40 | 17.92 | 19.46 | 20.74 | |
Earnings Yield |
2.97% | 4.02% | 4.38% | 5.03% | |
Free Cash Flow Yield |
(4.76%) | 2.26% | 6.76% | 7.12% | |
Revenue per Share |
5.29 | 6.23 | 4.80 | 5.31 | |
Operating CF per Share |
0.38 | 1.67 | 0.23 | 0.46 | |
Capex per Share |
(0.20) | (0.21) | (0.20) | (0.18) | |
Free Cash Flow per Share |
0.18 | 1.46 | 0.03 | 0.27 | |
Cash per Share |
2.45 | 3.43 | 3.28 | 2.25 | |
Shareholders Equity per Share |
13.01 | 13.11 | 14.04 | 13.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.01 | 13.11 | 14.04 | 13.96 | |
Free Cash Flow |
173.20 | 1,384.61 | 32.77 | 259.07 | |
Working Capital |
2,627.68 | 2,741.38 | 2,753.95 | 2,218.43 | |
Capital Expenditures |
(190.63) | (197.38) | (187.26) | (176.66) | |
Net Current Asset Value |
(7,573.31) | (6,813.30) | (7,097.31) | (6,854.12) | |
EV/EBIT |
23.31 | 18.79 | 17.93 | 15.71 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.03 | |
Price to Operating Income |
18.85 | 15.94 | 15.07 | 13.10 | |
| Other line items | |||||
Average Receivables |
4,048.70 | 4,150.20 | 3,766.77 | 3,979.52 | |
Average Payables |
1,898.56 | 2,086.24 | 2,128.50 | 3,010.77 | |
Average Inventory |
4,137.90 | 3,568.44 | 3,574.58 | 3,704.10 | |
Average Assets |
31,480.50 | 31,112.50 | 30,266.28 | 30,495.35 | |
Average Common Equity |
12,815.45 | 12,633.70 | 12,858.43 | 12,580.31 |
Columns are period end dates